文献速递前列腺增生与排尿功能障碍

良性前列腺增生新型手术干预再干预率的系统综述与网络Meta分析

Systematic review and network meta-analysis of re-intervention rates of new surgical interventions for benign prostatic hyperplasia.
PubMed 文献 · BJU Int · 2024-04-10

该系统综述与网络Meta分析评估UroLift、Aquablation、Rezum、前列腺动脉栓塞(PAE)和临时植入式镍钛装置(iTIND)等良性前列腺增生新型手术的再干预率。纳入32项研究共2400例患者,12个月再干预率Aquablation为0.01%、Rezum为0.02%、iTIND为0.03%、PAE为0.05%。网络Meta分析显示12个月排名最佳为经尿道前列腺电切术(TURP),其次为Aquablation、iTIND、Rezum和UroLift。

要点

  • 12个月再干预率:Aquablation 0.01%、Rezum 0.02%、iTIND 0.03%、PAE 0.05%。
  • 网络Meta分析12个月排名最佳为TURP,其次Aquablation、iTIND、Rezum、UroLift。
  • 这些新型手术再干预率与TURP相当,但需进一步研究直接比较。

核心结论

  • 系统综述与网络Meta分析显示,这些新型良性前列腺增生手术的再干预率在短期似乎与TURP相当,但需进一步研究直接比较这些不同术式。

研究设计与样本

  • 对2010年5月至2022年12月PubMed、Cochrane Library和Embase数据库进行系统综述与网络Meta分析,遵循PRISMA声明。
  • 纳入32项研究,包括10项随机对照试验和22项前瞻性观察性队列,共2400例参与者。

主要发现

  • 患者中位年龄66岁,中位前列腺体积51.9 mL,中位国际前列腺症状评分为22。
  • 12个月再干预率最低为Aquablation 0.01%,其次Rezum 0.02%、iTIND 0.03%、PAE 0.05%。
  • 网络Meta分析显示12个月排名最佳的治疗为经尿道前列腺电切术(TURP),其次为Aquablation、iTIND、Rezum和UroLift。
  • 这些新型良性前列腺增生干预的再干预率相当,尽管一些干预在较短期的结局报告优于TURP。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需进一步研究直接比较这些不同的良性前列腺增生术式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the re-intervention rates of new surgical benign prostatic hyperplasia (BPH) interventions, as the clinical durability of new surgical interventions for BPH is not widely known. METHODS: A critical review of new surgical BPH therapies namely 'UroLift®', 'Aquablation', 'Rezum', 'prostatic artery embolisation (PAE)' and 'temporary implantable nitinol device (iTIND)' was performed on PubMed, the Cochrane Library, and Embase databases between May 2010 and December 2022 according to the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) statement. All relevant articles were reviewed, and the risk of bias was evaluated using the Cochrane risk assessment tool and Newcastle-Ottawa Scale. RESULTS: Of the 32 studies included, there were 10 randomised controlled trials and 22 prospective observational cohorts. A total of 2400 participants were studied with a median patient age of 66 years, a median prostate volume of 51.9 mL, and a median International Prostate Symptom Score of 22. The lowest re-intervention rate at 12 months was for Aquablation at 0.01%, followed by Rezum at 0.02%, iTIND at 0.03%, and PAE at 0.05%. Network meta-analysis (NMA) showed that the best-ranked treatment at 12 months was transurethral resection of the prostate (TURP), followed by Aquablation, iTIND, Rezum, and UroLift. Re-intervention rates with these new BPH interventions are comparable, although some interventions reported better outcomes than TURP in the shorter term. CONCLUSIONS: While this systematic review and NMA showed that the re-intervention rate with these new surgical BPH interventions appears to be comparable to TURP in the short term, further studies are required to directly compare these various BPH procedures.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Shin BNH, Qu L, Rhee H, et al. Systematic review and network meta-analysis of re-intervention rates of new surgical interventions for benign prostatic hyperplasia. BJU Int. 2024. PMID: 38600763. doi:10.1111/bju.16304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。